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a  b  s  t  r  a  c  t
Aim: To present a review of the contemporary surgical management of skull base tumors.
Background: Over the last two decades, the treatment of skull base tumors has evolved
from  observation, to partial resection combined with other therapy modalities, to gross
total  resection and no adjuvant treatment with good surgical results and excellent clinical
outcomes.
Materials and methods: The literature review of current surgical strategies and management
of  skull base tumors was performed and complemented with the experience of Barrow
Neurological Institute.
Results: Skull base tumors include meningiomas, pituitary tumors, sellar/parasellar tumors,
vestibular and trigeminal schwannomas, esthesioneuroblastomas, chordomas, chon-
drosarcomas, and metastases. Surgical approaches include the modified orbitozygomatic,
pterional, middle fossa, retrosigmoid, far lateral craniotomy, midline suboccipital cran-
iotomy, and a combination of these approaches. The selection of an appropriate surgical
approach depends on the characteristics of the patient and the tumor, as well  as the expe-
rience  of the neurosurgeon.
Conclusion: Modern microsurgical techniques, diagnostic imaging, intraoperative neuron-
avigation, and endoscopic technology have remarkably changed the concept of skull basesurgery. These refinements have extended the boundaries of tumor resection with minimal
morbidity.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
exposure by means of bony resection in order to mini-.  Background
ntil the later decades of 20th century, lesions located at the
ase of the skull were considered inoperable. The introduction
f microsurgical techniques, advances in neuroanesthesi-
logy, magnetic resonance imaging (MRI), neuronavigation,
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dramatically changed the management of these tumors.
The main goal of these techniques is to enhance surgicalrological Institute, St. Joseph’s Hospital and Medical Center, 350
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mize the need for brain retraction. When brain retraction
is necessary, experienced neurosurgeons have replaced fixed
retraction with dynamic retraction, thus limiting the risk of
rban & Partner Sp. z o.o. All rights reserved.
d rad326  reports of practical oncology an
injury to underlying brain.1 Patient positioning that enhances
gravity retraction, extensive dissection of arachnoid planes,
the refinement of microsurgical instrumentation, appropri-
ate selection of operative corridors, and neuronavigation
have all been used to improve patient outcomes and reduce
morbidities.1–4 The key principle of skull base surgery is to
deconstruct the bony skull base around the brain to create
safe apertures to resect deep-seated pathologies.
2.  Materials  and  methods
A review of English-language literature was performed on
PubMed on contemporary surgical strategies and manage-
ment of skull base tumors was performed. This review was
complemented with knowledge gained from surgical results
and the clinical outcome experience of patients treated at
Barrow Neurological Institute.
3.  Results
Skull base tumors include meningiomas, pituitary tumors,
sellar/parasellar tumors, vestibular and trigeminal schwanno-
mas, esthesioneuroblastomas, chordomas, chondrosarcomas,
and metastases. Surgical approaches to the anterior and mid-
dle skull base include orbitozygomatic craniotomy or modified
orbitozygomatic craniotomy, pterional craniotomy, and mid-
dle fossa craniotomy, anterior and posterior transpetrosal
approach. Surgical approaches to the posterior fossa include
retrosigmoid craniotomy, extended (mastoidectomy, petrosec-
tomy) retrosigmoid craniotomy, far lateral craniotomy, and
midline suboccipital craniotomy. The selection of an appro-
priate surgical approach depends on the characteristics of the
tumor (size, type, vascularity, and anatomical relations with
the normal brain and/or brainstem) and the experience of the
neurosurgeon.
4.  Discussion
4.1.  General  classifications  and  epidemiology
Skull base tumors can generally be classified as either
benign (meningiomas, sellar/parasellar tumors, vestibular
and trigeminal schwannomas)5 or malignant (chordoma,
chondrosarcoma, metastasis),5 although there is a crossover.
The incidence of skull base meningiomas is 2 per 100,000 per
year. The incidence of pituitary tumors and vestibular schwan-
nomas is 1 per 100,000 per year.5 Skull base metastases are
more common and have an incidence of 18 per 100,000 per
year.6 The skull base can be invaded by malignancies orig-
inating from the sinonasal tract (esthesioneuroblastoma),7
the nasopharynx (squamous cell carcinoma),8 the orophar-
ynx, the ear region, and the orbit (meningioma, osteoma,
rhabdomyosarcoma).54.2.  Meningiomas
Meningiomas are the most common primary skull base
tumors.5 The mainstay of treatment for skull baseiotherapy 2 1 ( 2 0 1 6 ) 325–335
meningiomas is surgical resection. The surgical approach
depends upon the location and size of the tumor. Large
tumors may need to be resected in several stages and may
require more  than one surgical approach. Surgical plan-
ning is tailored according to the tumor location and size.
Complete surgical resection should be the primary goal.
Occasionally, tumors can be firmly attached to the arteries
and cranial nerves, making gross total resection impossible.
Preoperative angiography and tumor embolization can be
useful, but they are rarely necessary.9 The 5-year recur-
rence rate for a totally resected World Health Organization
grade I meningioma is 5%, 40% for grade II, and 50–80% for
grade III.
4.3.  Anterior  and  middle  skull  base  meningiomas
Anterior skull base meningiomas include olfactory groove,
planum sphenoidale, and tuberculum sellae meningiomas
(Figs. 1 and 2).10–13 The blood supply to these tumors can come
from branches of the ethmoidal, meningeal, and ophthalmic
arteries. Large tumors can also be supplied by branches of the
anterior cerebral artery (A2, frontopolar) (Fig. 2). The olfac-
tory nerves are typically involved, being either displaced or
adherent to the tumor. Although preservation of these nerves
is challenging, it should be attempted. Even though patients
might present as anosmic, return of olfaction after the tumor
resection is possible (Fig. 1).14 Surgical approaches to these
tumors include unilateral frontal, bilateral frontal, modified
orbitozygomatic, and pterional approaches.5 The decision for
an approach is made based on the tumor size, extension, size
of the frontal sinus, and surgeon’s preference. After exposing
the lesion, in general, early devascularization of the tumor is
preferred. The next step is tumor debulking, which begins with
internal debulking and is followed by dissecting the capsule
from adjacent structures and folding it in. Reaching the pos-
terior tumor capsule can be the most challenging step, because
branches of the anterior cerebral artery might be attached
to or encased in the tumor. Even though there is usually an
arachnoid plane between the tumor and optic nerve, metic-
ulous dissection is needed to prevent optic nerve damage
(Figs. 1 and 2).
Sphenoid wing meningiomas are typically favorable for
surgical resection; however, they have the potential to
increase the internal carotid artery (ICA), cavernous sinus, and
optic apparatus. Based on location, sphenoid wing menin-
giomas can be subclassified in spheno-orbital (en plaque or
hyperostotic) and globoid meningiomas.15,16 Sphenoid wing
meningiomas can be resected through a pterional or orbitozy-
gomatic craniotomy. Lateral sphenoid wing meningiomas are
frequently associated with hyperostosis. In those cases, the
craniotomy should be planned to extend beyond the bony infil-
tration, and extensive skull base drilling is frequently required
to completely remove the lesion. Extradural approaches facili-
tate access to the orbit, middle fossa, the superior and inferior
orbital fissures, as well as the cavernous sinus, while minimiz-
ing trauma to the brain from retraction.Ideally, a 1-cm tumor free margin of dura should be
removed; however, this is frequently not possible when deal-
ing with skull base lesions. Common complications associated
with resection of anterior and middle fossa meningiomas
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Fig. 1 – Anterior skull base meningioma. A 65-year-old-female presented with left blurry vision. (A) T1-weighted axial
magnetic resonance imaging (MRI) with gadolinium showing a left clinoidal meningioma. The patient underwent a left
pterional craniotomy and tumor resection. (B and C) Intraoperative microscopic views of the tumor (arrow) pre- (B) and
postresection (C). Even though the olfactory nerve was tightly adhered to the tumor, the nerve (OLPH) is preserved intact.
Observe the anatomic relation of the olfactory nerve with the optic nerve (ON) and internal carotid artery (ICA). D,






























nclude anosmia (10–20%), cerebrospinal fluid (CSF) leak (10%),
nd visual disturbances and hemorrhage (5–10%).17
.4.  Posterior  skull  base  meningiomas
osterior fossa meningiomas comprise 10% of intracranial
eningiomas. They are classified by their anatomical ori-
in and include clival, petroclival, cerebellopontine angle
CPA), pineal region, foramen magnum,  jugular foramen, and
entorial meningiomas (Fig. 3).1,18,19 The diagnosis is gen-
rally made radiographically and the preoperative work-up
ncludes MRI  and computed tomography. Magnetic resonance
enograms can be useful to evaluate venous anatomy, domi-
ance of transverse/sigmoid sinuses, temporal lobe draining
atterns, and jugular bulb size. Cerebral angiograms with pre-
perative embolization can be useful in the management of
ome meningiomas.9 Due to the limited space within the pos-
erior fossa, adequate bony exposure and early CSF drainage
re essential. Hydrocephalus is a common clinical presen-
ation for patients with posterior fossa tumors; therefore, a
reoperative ventriculoperitoneal shunt or external ventricu-
ar catheter placement is recommended.
Petroclival meningiomas can extend from the jugu-
ar foramen up to the posterior clinoid (Fig. 3C and
). Petroclival meningiomas represent one of the most
hallenging meningiomas to treat. Different approaches
sed to access these tumors include the orbitozygomatic,
ransbasal, subtemporal–transtentorial, transpetrosal (ante-
ior transpetrous approach), and retrosigmoid. Combined
pproaches are frequently necessary for larger tumors.
he combined supra-infratentorial transpetrosal approach
xposes the middle and inferior clival region.18,20CPA meningiomas are usually treated through a retrosig-
moid approach. The blood supply for CPA meningiomas
typically originates from the dura of the petrous portion of
the temporal bone and sometimes is difficult to interrupt after
significant tumor removal. Resection typically begins with
internal debulking followed by dissection of the tumor off
the cerebellum, brainstem, and cranial nerves. Pitfalls include
cranial nerve (V, VII, VIII, IX–XI) and arterial (anterior and pos-
terior inferior cerebellar arteries) injuries.21
Foramen magnum meningiomas account for 4–20% of
posterior fossa meningiomas (Fig. 3A and B).19 Surgi-
cal approaches include the standard midline suboccipital
approach with C1 laminectomy, transoral approach, and far
lateral approach. The location of the tumor (anterior vs. poste-
rior) in relation to the spinal cord determines the ideal surgical
approach. Preoperative considerations include the relation-
ship of the tumor to the vertebral arteries and their patency,
the functional status of the lower cranial nerves, size of the
tumor, degree of brainstem/spinal cord compression, and vas-
cularity of the tumor (Fig. 3).19 Complications of posterior
fossa meningioma resection include brainstem and cerebel-
lum swelling (sometimes requiring surgical decompression),
venous infarction, cranial nerve injury, vertebral artery
injury, hydrocephalus, CSF leak, pseudomeningocele, and
infection.
4.5.  Pituitary  adenomasPituitary adenomas can be classified as functioning (secreting)
or nonfunctioning (nonsecreting) tumors. Lesions ≤10 mm in
size are considered microadenomas and those >10 mm are
macroadenomas. Symptoms are related to the tumor size
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Fig. 2 – Planum sphenoidale/tuberculum sellae meningioma. A 39-year-old-male presented with headaches, visual
disturbances, and papilledema. A (coronal) and B (sagittal), T1-weighted MRIs with gadolinium show a large planum
sphenoidale/tuberculum sellae meningioma with mass effect on both frontal lobes. The tumor is deforming the third
ventricle, causing hydrocephalus. Also notice that both anterior cerebral arteries are stretched and deformed (A, arrows) by
the tumor mass. The patient underwent a subfrontal craniotomy and interhemispheric approach for tumor resection. During
the microsurgical resection, part of the tumor was extremely adhered to the roof of the third ventricle and fornices. This part
of the tumor was not resected. C (coronal) and D (sagittal), postoperative MRIs show almost complete gross total resection.
The patient will be managed conservatively with serial imaging. Used with permission from Barrow Neurological Institute.and functioning status. Around 97% of microadenomas and
70% of macroadenomas are secreting.22 With the exception of
prolactin secreting tumors, the initial treatment for pituitary
adenomas is surgical resection. Pharmacological and radia-
tion therapies are sometimes necessary for certain types of
tumors. A transsphenoidal approach is most commonly used,
except for large tumors with suprasellar extension that require
a supratentorial approach. Minimally invasive endoscopic
approaches are becoming more  commonly used. The advan-
tages of the endoscopic approach include better illumination
and improved corner visualization. Results are similar to those
with open microscopic surgery.23 Major risks include ICA,
optic nerve, and hypothalamic injuries. Other complicationsinclude CSF leak, meningitis, intracranial hemorrhage, and
nasal sinus infection.
4.6.  Sellar  and  parasellar  tumors
Sellar and parasellar lesions include a wide variety of tumors
such as pituitary adenomas, craniopharyngiomas, menin-
giomas, gliomas, neuromas, hemangiomas, germ cell tumors,
epidermoid/dermoid cysts, paragangliomas, hamartomas,
lymphomas, and metastases. Although transsphenoidal
surgery is preferred, transcranial approaches with skull base
techniques are often necessary. Indications for transcra-
nial approaches are optic apparatus decompression, tumor
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Fig. 3 – Foramen magnum meningioma and petroclival meningioma. A and B, a 53-year-old-male presented with dizziness
and vertigo. The T1-weighted coronal MRI  (A) with gadolinium shows a right-side lateral foramen magnum meningioma
causing mass effect on the brainstem and spinal cord. The patient underwent a right far lateral suboccipital craniotomy
with C1 laminectomy and tumor resection. Postoperative coronal MRI  (B) demonstrates complete surgical resection. C and D,
a 63-year-old male with diplopia, ataxia, and decreased hearing. The T1-weighted axial MRI  with gadolinium (C)
demonstrates a large left petroclival meningioma causing brainstem compression. Notice that the tumor is infiltrating into
the cavernous sinus. The patient underwent a left retrosigmoid craniotomy and tumor resection. The postoperative axial











xtension beyond a transsphenoidal reach (above the level of
he middle part of the third ventricle, beyond the midplane of
arotid arteries, and higher than the tip of the basilar artery),
vidence of a dural tail, and a firm consistency with intimate
dherence to the neurovascular structures.
The two classic surgical approaches to this region are
he pterional and orbitozygomatic craniotomies. We  prefer
he modified orbitozygomatic craniotomy because it gives
ccess to the parasellar region, while minimizing soft tis-
ue dissection and bony removal. Removal of the orbitalrim and roof facilitates the mobilization of the optic nerve,
providing better access through the opticocarotid window.
An interhemispheric approach is sometimes necessary when
tumors extend high into the third ventricle. A subfrontal
approach is useful when the lesion invades the nasal
sinuses, orbits, or upper clivus; it also provides access to the
third ventricle through the lamina terminalis. Transcranial
approaches to the sellar/parasellar region provide better expo-
sure to the microvasculature of the hypothalamus and visual
apparatus.
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Fig. 4 – Vestibular schwannoma. A 49-year-old-female presented with left side decreased hearing. (A) T1-weighted axial
MRI  with gadolinium shows a cystic cerebellopontine tumor causing mass effect on the cerebellum and brainstem. The
patient underwent a left retrosigmoid craniotomy and tumor resection. (B–D) Intraoperative microscopic images show the
tumor before resection (arrow) (B), after drilling the internal auditory canal (C), and after complete resection (D). Notice that
the vestibular (V) and facial (F) cranial nerves were preserved. E, postoperative axial MRI  demonstrates gross total resection.
Used with permission from Barrow Neurological Institute.4.7.  Craniopharyngiomas
Craniopharyngiomas are benign, extra-axial, intra-arachnoid
neoplasms that originate from the craniopharyngeal duct
(oral cavity to Rathke’s pouch). There are two histological
subtypes: adamantinomatous (95% of pediatric cases) and
papillary squamous epithelium. Their incidence is about 0.1
per 100,000 per year. The majority of these tumors (>80%) are
suprasellar.24 Symptoms are related to endocrine dysfunction
(present in 80% of patients) and obstructive hydrocephalus.
Complete surgical resection is an important prognostic factor
for recurrence. However, total resection is frequently not pos-
sible due to the fact that these tumors can tightly adhere to the
floor of the third ventricle, hypothalamus, and optic chiasm.
Other treatment modalities are often necessary, including
radiosurgery, radiation, intracystic chemotherapy, and cystic
catheter insertion with intermittent cyst aspiration.
Surgical approaches include pterional, orbitozygomatic,
subfrontal/translamina terminalis, interhemispheric tran-
scallosal, and endoscopic variations.25 Our preference is the
modified orbitozygomatic craniotomy as it provides access to
pre- and retrochiasmatic lesions, and areas above and below
the diaphragm sellae. The lamina terminalis is easily opened
to provide access to the third ventricle. For large midline
tumors with extension into the third ventricle and foramen
of Monro, an interhemispheric transcallosal approach is nec-
essary. Gross total resection rates vary from 50% to 90%.
The rates of gross total resection are higher in children than
in adults. Recurrence rates after gross total resection vary
from 0% to 50% at 10 years. Postoperative morbidity hasbeen reported to be 1.7–5.4%. Visual decline after aggressive
resection occurs in 4% to 30% of patients. Endocrinopathies
are frequent postoperatively, with diabetes insipidus, either
transient or permanent, being the most common.26
4.8.  Vestibular  schwannoma
Vestibular schwannomas have an incidence of 1 per 100,000
per year; this rate has increased during recent years due to
the routine use of brain MRI. The growth rate of these tumors
usually guides decisions on treatment versus observation.
Growth rates vary from 0.4 to 2.4 mm/yr. Typically, extrameatal
tumors have faster growth rates than intrameatal lesions.27–29
Cystic tumors and those related to neurofibromatosis type 2
also tend to have a more  aggressive course and are associ-
ated with a more  rapid neurological deterioration. Vestibular
schwannomas are the most common tumors diagnosed in the
cerebellopontine angle (70–80%). MRI with a specific internal
auditory canal protocol provides anatomical information nec-
essary for surgical planning and should be obtained routinely
(Fig. 4). The treatment goals and surgical approach should
be individualized based on characteristics of the patient (age,
hearing status) and the tumor (size, cystic).30
Three main surgical approaches are used for treating
vestibular schwannomas: retrosigmoid, middle fossa, and
translabyrinthine.27–29 The retrosigmoid approach is familiar
to neurosurgeons and can be used to address large tumors
compressing the brainstem as well as small intracanalicular
tumors. It gives an extraordinary view of the cranial nerves
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rst step is to open the cisterna magna and drain CSF. This step
s crucial in any CPA surgery to reduce cerebellar retraction
nd facilitate arachnoid dissection and tumor resection.
nother critical step during resection of acoustic neuromas is
he identification of the seventh and eighth cranial nerves. The
acial nerve is typically found anteriorly in the middle third
f the capsule.27 Brainstem auditor evoked responses (BAERs)
nd a hand-held nerve stimulator are routinely ordered for
hese cases. The posterior wall of the internal auditory canal
s drilled off to expose the intracanalicular portion of the
umor, when necessary, to achieve a gross total resection
Fig. 4), and also for early identification of the facial nerve.
he translabyrinthine approach has the advantage of early
acial nerve identification, but is not appropriate if hearing
reservation is the goal. Exposure requires a mastoidectomy
nd labyrinthectomy with skeletonization of the facial nerve.
sually, an arachnoid plane is found between the nerve and
he tumor. Large tumors are debulked first and then dissected
ff the nerve. The facial nerve is most frequently found along
he anterior margin of the tumor or splayed over the top of the
umor. With this approach, the medial aspect of the tumor
ttached to the brainstem is the most challenging portion
f the dissection. The middle cranial fossa approach is indi-
ated for small laterally located intracanalicular tumors when
earing preservation is the goal.28,31 Common complications
ay include CSF leak (4–27%), hearing loss, facial nerve palsy,
ower cranial nerve palsy, cerebellar contusion, air embolism
if using a sitting position), and infection. Radiosurgery is used
or the management of small tumors (usually less than 2 cms)
r residual tumor.
.9.  Trigeminal  schwannomas
rigeminal schwannomas are rare benign skull base tumors.
hey account for 0.07% to 0.36% of all intracranial tumors.
rigeminal schwannomas commonly originate from the
asserian ganglion, have a dumbbell shape, and can extend
nto the middle fossa (most commonly), posterior cranial
ossa, and the extracranial space. These tumors have been
lassified based on their anatomic extension and shape into
ype A (middle fossa), type B (posterior fossa), type C (dumb-
ell), and type D (extracranial).32,33
Surgical resection remains the definitive treatment, and
he location of the tumor dictates the surgical approach.
ype A tumors can be approached through a pterional or
rbitozygomatic extradural or transsylvian exposure and
ia a subtemporal intradural approach. Type B tumors are
redominantly located within the CPA and a classic retrosig-
oid craniotomy exposes the tumor; however, if the tumor
xtends into the middle fossa, a transpetrosal or combined
ranspetrosal approach is necessary. Type C tumors are more
hallenging and multiple approaches are often necessary.
rbitozygomatic, petrosal, and combinations of these two
pproaches have resulted in satisfactory patient outcomes.
e have used the modified orbitozygomatic craniotomy and
ound that it provides excellent access to the posterior fossa
hrough Meckel’s cave. Type D tumors extend inferiorly into
he infratemporal fossa and cranial foramina, requiring a
reauricular–infratemporal approach. Patient outcomes have
ramatically changed with modern neurosurgical techniques.therapy 2 1 ( 2 0 1 6 ) 325–335 331
Gross total resections are achieved in 75–100% of reported
cases.34,35
4.10.  Cavernous  sinus  tumors
Surgical approaches to the cavernous sinus, once called “no
man’s land” have changed dramatically with the modern
era of microneurosurgery. Primary cavernous sinus menin-
giomas are rare (<3% of all meningiomas) and attempts at
subtotal or total resection of these lesions increase the like-
lihood of iatrogenic worsening or new cranial nerve deficits.
Our current practice is to consider resection for extracav-
ernous portions of the tumor, or to biopsy intracavernous
tumors, if a tissue diagnosis is required. Depending on the
tumor location within the cavernous sinus, two different
approaches can be used. The anterior cavernous sinus can
be approached through a temporopolar extradural or fron-
totemporal (modified orbitozygomatic) intradural approach,
and the posterior cavernous sinus can be accessed through
an anterior transpetrosal approach. For skull base menin-
giomas with cavernous sinus involvement, tumor control is
achievable with extra cavernous resection alone in up to
90% of cases. Patients with atypical and more  aggressive
tumors may require radical resections with ICA sacrifice and
cerebral revascularization.36,37 Adjuvant therapy with stereo-
tactic radiosurgery has shown good control rates for skull
base meningiomas and can be considered in patients with
tumor progression whose tumors are not amenable to surgi-
cal resection. Radiosurgery, including heavy charged particle
irradiation, play an important role as an adjuvant to the man-
agement of cavernous sinus lesion, however it is beyond the
scope of this work.
4.11.  Glomus  tumors  (paraglanglioma)
Glomus tumors (paraglangliomas) are rare, with an incidence
of 1 to 3 cases per million people and a strong female pre-
dominance (6:1). These tumors are indolent, with a slow,
locally invasive growth pattern. Clinical symptoms are related
to the location of the tumor. The temporal bone, middle
ear, jugular foramen, hypoglossal canal, and clivus are com-
monly involved. Less commonly, these lesions can extend into
the cavernous sinus and sellar/parasellar region or metas-
tasize (pulmonary and gastrointestinal tract). Findings on
computed tomography of the head include bony destruc-
tion/remodeling (enlarged jugular foramen and erosion of
petroclival junction). These tumors are very vascular lesions
that can be supplied by the ascending pharyngeal (poste-
rior meningeal branches), internal maxillary, occipital, and
internal carotid arteries. The ideal management for resectable
tumors is embolization9 followed by surgical resection.38 That
these are primarily extradural tumors helps to facilitate a
complete surgical resection. The lateral skull base approach
involves an extensive craniocervical dissection, a complete
mastoidectomy, and C1 laminectomy with ligation of the sig-
moid sinus. Major morbidities include facial paralysis, hearing
loss, and lower cranial nerve injuries. The infratemporal fossa
approach extends rostrally into the ear canal to expose the
ICA up to the cavernous sinus.39 Gross total resection has
been reported in up to 90% of cases. However, functional
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Fig. 5 – Chordoma and chondrosarcoma. (A–C) A 67-year-old-male with a chordoma that was initially diagnosed at the age
of 55 (A, sagittal MRI). He underwent multiple resections for tumor recurrences. Twelve years after the original diagnosis
and 2 years after “complete” surgical resection, he presented with a large, infiltrative recurrence (B and C, axial and coronal
MRIs, respectively). Notice the tumor extension into the ethmoid sinuses, cavernous sinus and right orbit. (D–F)
37-year-old-female with progressive right cranial nerve deficits (III, VI, VII and VIII) was found to have a skull base
chondrosarcoma. Axial MRI  pre- (D) and axial and coronal MRIs postcontrast (E and F) show the skull base mass lesion.
These lesions required repeated extradural middle cranial fossa approaches for tumor control. Used with permission from
Barrow Neurological Institute.
recovery is rare and morbidity is significant. Morbidity is
largely due to facial palsy, hearing loss, and lower cranial nerve
palsies.40
4.12.  Chordomas  and  chondrosarcomas
Chordomas and chondrosarcomas are rare, benign tumors
that originate from cells of the notochord. These slow-growing
tumors are locally destructive (Fig. 5). The incidence is 0.08
per 100,000 per year, being most common in white males.
Radiographically, chordomas and chondrosarcomas are indis-
tinguishable except for the location. Chondrosarcomas arise
from a more  paramedian location (Fig. 5D–F), whereas chor-
domas originate in the midline (Fig. 5A–C). Both tumors can
grow into the nasopharynx, orbits, and sella. Local bony
destruction and invasion can make oncologic excision very
difficult.41 Because these tumors are relatively insensitive toradiation and chemotherapy, surgery is the primary treatment
modality.
The appropriate surgical approach is based on size
and location. Midline upper clival tumors are approached
anteriorly via transphenoidal, subfrontal, transpharyngeal
transpalatal approaches; lateral clival and paraclinoid tumors
can be accessed through an orbitozygomatic approach; and
posterior or lateral extension can require a middle fossa or
transpetrosal approach.42 Tumors at the lower clivus or fora-
men magnum often require an oral or a far lateral approach.
Two or more  approaches are sometimes necessary to treat
a single tumor. The core of these tumors usually has a soft
gelatinous consistency that can readily be aspirated. The
fibrous outer layer is classically more  difficult to resect because
it may be firmly attached to the brainstem and neurovas-
cular structures. Chordomas tend to invade into cancellous
bone. Local recurrence is responsible for the greatest amount
of morbidity and mortality in these patients (Fig. 5A–C).43
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Fig. 6 – Esthesioneuroblastoma. A 25-year-old male presented with headaches, anosmia, and seizures. (A–C) Coronal,
sagittal, and axial (respectively) T1-weighted MRIs with gadolinium demonstrate a large enhancing mass extending down



































ccupies the entire anterior cranial base. Used with permiss
hondrosarcomas are much less aggressive and these patients
ave a higher rate of recurrence-free survival.41
.13.  Esthesioneuroblastoma
sthesioneuroblastoma is a rare tumor that arises from the
lfactory epithelium and can extend into the skull base,
aranasal sinuses, and orbits (Fig. 6). Esthesioneuroblas-
omas account for up to 2–3% of all intranasal neoplasms. A
ultidisciplinary team approach, including a neurosurgeon,
phthalmologist, otolaryngologist, and medical and radia-
ion oncologists, is usually required.44,45 Surgical resection
s the mainstay of therapy for these tumors. Gross total
esection results in a statistically significant improvement in
utcome. Neoadjuvant radiation and chemotherapy, adminis-
ered before surgery, have been used to decrease tumor mass
nd minimize local tumor dissemination and distant metas-
asis during surgery.44,45
The surgical approach most commonly used is a bifrontal
raniotomy through a bicoronal incision with pericranial
ap preservation for skull base reconstruction. The bifrontal
raniotomy is accompanied with exenteration of the frontal
nd ethmoidal sinuses if necessary. Skull base osteotomies
ave to be carefully planned so that they extend beyond
he tumor margins. Frozen specimens are examined intra-
peratively to verify tumor free margins. The most common
omplications include CSF leak, intracranial infection, and
emorrhage. Meticulous skull base reconstruction is manda-
ory. Dead spaces are voided and obliterated with free fat grafts
nd fibrin glue. With current management, patients have 1-
ear, 5-year, and 10-year disease-free survival rates of 97%,
3%, and 62.8%, respectively.46 Recurrence is common (14%)
ven after gross total resection with a mean follow-up of 8
ears, and recurrence is most commonly found at 4 years.46,47
rain, lung, and bone are the most common sites of distal
etastases.48rom Barrow Neurological Institute.
4.14.  Craniofacial  malignancies
Sinonasal malignancies account for most of the craniofacial
malignancies. They account for less than 3% of the upper
aerodigestive tract. Around 60–70% arise from the maxillary
sinus, 10–15% from the ethmoid sinuses, the remaining from
the frontal and sphenoid ones.49 Sinonasal malignancies can
grow to a considerable size before developing any concerns,
hence, late presentation is a common occurrence. Craniofacial
malignancies include squamous cell carcinoma which is the
most common. It erodes through the bony margins of the nose
and sinuses and invades the orbit, ethmoidal roof and cribri-
form plate into the anterior skull base. Best treatment results
from chemoradiotherapy followed by aggressive surgery. A 5-
year survival is 30%.50,51 Adenocarcinoma is related to wood
dust exposure. Treatment is surgical. A 5-year survival is
around 45%.52 Adenoid cyst carcinoma is a slow-growing
tumor but has the capacity for widespread local dissemination
by perineuronal spread. Olfactory neuroblastoma involves the
cribriform plate and the olfactory bulb. The 5-year survival
rates are 80% with complete surgical resection. Anaplastic
carcinoma, sinonasal undifferentiated carcinoma, and malig-
nant melanoma has the worst prognosis.53–55 Management
is best accomplished by a multidisciplinary team. Details of
the surgical approaches are out of the scope of this article
but some principles are worth mentioning and they include:
adequate exposure and oncological resection of the tumor,
minimal or no brain retraction, watertight dural closure using
dural patch (fascia lata, pericranial flap) if necessary, metic-
ulous reconstruction of the skull base and optimal esthetic
outcome.4.15.  Skull  base  metastasis
Cranial base metastasis occurs in approximately 4% of can-
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lung, renal, and prostate.6,57 Indications for surgical resection
are to obtain a pathological diagnosis in cases of unknown pri-
mary tumors, to provide symptomatic relief, decrease mass
effect, and remove solitary metastasis.56
The surgical approach depends on the location of the
tumor. A recent analysis of patients with skull base metastases
showed that the anterior cranial fossa was the most common
location (51.8%) followed by middle fossa. Currently, radiother-
apy/stereotactic radiosurgery are the first line of treatment
for skull base metastases, particularly for tumors sensitive
to radiation (lung, breast, prostate). The main limitations of
radiation therapy are related to the size of the lesion and the
proximity to critical structures, such as the optic nerve and
brainstem. On the other hand, melanoma, renal cell carci-
noma, and most sarcomas are relatively radiotherapy resistant
and surgery should be considered. The ideal candidate for
surgery is a patient with a well-controlled systematic dis-
ease, good functional status, and a relatively long expected
survival.6,56,57
5.  Conclusion
The contemporary surgical management of skull base tumors
offers satisfactory surgical results and good to excellent
clinical outcomes. Modern microsurgical techniques, diagnos-
tic imaging, intraoperative neuronavigation, and endoscopic
technology have remarkably changed the concept of skull base
surgery. These refinements have extended the boundaries of
tumor resection and obviated the need for adjuvant thera-
pies in some patients with benign tumors. In some cases, the
main goal of skull base surgery is not the complete removal
of the lesion, but the improvement of quality of life and the
prolongation of the disease free survival time. For patients
with skull base malignancies, a multidisciplinary approach
is mandatory to plan treatments that incorporate surgery,
radiation, and chemotherapy to maximize the patients’
outcomes.
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